Journal
FRONTIERS IN CARDIOVASCULAR MEDICINE
Volume 8, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcvm.2021.668532
Keywords
atherosclerosis; metabolites; therapies; plaque stability; gut microbiota
Categories
Funding
- National Natural Science Foundation of China [82070455, 81770450]
- Open Project Program of Guangxi Key Laboratory of Centre ofDiabetic Systems Medicine [GKLCDSM-20210101-02]
- Research and Innovation Funding Project for College Students in Experimental Animal Center of Jiangsu University
- Postgraduate Research and Practice Innovation Program of Jiangsu Province [KYCX20_2881, SJKY19_2585]
- Zhenjiang Cardiovascular Clinical Research Center Project [SS2018008]
Ask authors/readers for more resources
Cardiovascular diseases are major causes of mortality and morbidity in modern society. Recent studies have found relationships between microbiota and atherosclerosis, influencing the stability of atherosclerotic plaque. Therapies based on microbiota and its metabolites are being explored for treatment.
Cardiovascular diseases (CVDs) are major causes of mortality and morbidity in the modern society. The rupture of atherosclerotic plaque can induce thrombus formation, which is the main cause of acute cardiovascular events. Recently, many studies have demonstrated that there are some relationships between microbiota and atherosclerosis. In this review, we will focus on the effect of the microbiota and the microbe-derived metabolites, including trimethylamine-N-oxide (TMAO), short-chain fatty acids (SCFAs), and lipopolysaccharide (LPS), on the stability of atherosclerotic plaque. Finally, we will conclude with some therapies based on the microbiota and its metabolites.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
